New Four-in-One antibody tackles tough leukemia
NCT ID NCT05944978
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This early-phase study tests a new drug called GNC-035 in people whose chronic lymphocytic leukemia (CLL) has come back or stopped responding to treatment. The drug is a tetra-specific antibody designed to attack cancer cells in multiple ways. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Only 3 participants were enrolled in this part of the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.